Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.
Randomized study in people · 2009
- What was studied
- 567 treated participants with type 2 diabetes and symptomatic polyneuropathy
- Main finding
- Neuropathic symptoms improved versus placebo. The vibration-threshold coprimary analysis over time did not reach statistical significance, although the final-visit comparison did.
TSS exposure-adjusted difference · −0.56 points; 95% CI −0.85 to −0.27 · p=0.0003
Reported findings and study design
567 diabetic-neuropathy patients: Actovegin 281 versus placebo 286. Twenty IV infusions 2,000 mg/day, then oral 1,800 mg/day for 140 days; total 160 days.
Population or model 567 treated participants with type 2 diabetes and symptomatic polyneuropathy
Dose, route and schedule
Actovegin: 20 intravenous infusions at 2,000 mg/day, followed by oral treatment at 1,800 mg/day for 140 days in diabetic polyneuropathy.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| TSS exposure-adjusted difference | −0.56 points; 95% CI −0.85 to −0.27 | p=0.0003 |
| TSS baseline-to-day-160 difference | −0.86 points; 95% CI −1.22 to −0.50 | p<0.0001 |
| Vibration threshold, exposure-adjusted | 3% decrease; 95% CI 0–6% | p=0.084 |
| Vibration threshold at day 160 | 5% decrease; 95% CI 1–9% | p=0.017 |
| NIS-LL sensory function | −0.25; 95% CI −0.46 to −0.04 | p=0.021 |
| Adverse-event incidence | No between-group difference reported |
The nonsignificant exposure-adjusted vibration endpoint is preserved alongside the significant end-of-study result.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- Endpoint timing matters; these findings do not establish general nerve regeneration or benefit in healthy people. No difference in adverse-event incidence was reported during this trial.
Source details
Journal publication
Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Sources checked
Citation
Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes care
Study source ↗ · DOI 10.2337/dc09-0545 · Bibliography entry · Link to this summary